PubRank

Guillermo Izquierdo

Author PubWeight™ 58.30‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010 13.82
2 Antigen microarrays identify unique serum autoantibody signatures in clinical and pathologic subtypes of multiple sclerosis. Proc Natl Acad Sci U S A 2008 2.57
3 Toll-like receptor 2 and poly(ADP-ribose) polymerase 1 promote central nervous system neuroinflammation in progressive EAE. Nat Immunol 2009 2.56
4 Fingolimod after natalizumab and the risk of short-term relapse. Neurology 2014 1.96
5 TNFRSF1A polymorphisms rs1800693 and rs4149584 in patients with multiple sclerosis. Neurology 2013 1.47
6 [Neuropathy due to elongation of the ilioinguinal nerve]. Rev Neurol 2010 1.38
7 Differential cognitive impairment for diverse forms of multiple sclerosis. BMC Neurosci 2006 1.19
8 Geographical variations in sex ratio trends over time in multiple sclerosis. PLoS One 2012 1.12
9 Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS. J Neurol 2013 1.06
10 Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis. Ann Neurol 2015 1.04
11 IL2RA/CD25 gene polymorphisms: uneven association with multiple sclerosis (MS) and type 1 diabetes (T1D). PLoS One 2009 1.04
12 Immunological markers of optimal response to natalizumab in multiple sclerosis. Arch Neurol 2012 1.03
13 Country, sex, EDSS change and therapy choice independently predict treatment discontinuation in multiple sclerosis and clinically isolated syndrome. PLoS One 2012 1.02
14 MANBA, CXCR5, SOX8, RPS6KB1 and ZBTB46 are genetic risk loci for multiple sclerosis. Brain 2013 0.94
15 Seasonal variation of relapse rate in multiple sclerosis is latitude dependent. Ann Neurol 2014 0.91
16 The high producer variant of the Fc-receptor like-3 (FCRL3) gene is involved in protection against multiple sclerosis. J Neuroimmunol 2008 0.91
17 Multiple sclerosis risk variant HLA-DRB1*1501 associates with high expression of DRB1 gene in different human populations. PLoS One 2012 0.90
18 Genome-wide association study of multiple sclerosis confirms a novel locus at 5p13.1. PLoS One 2012 0.90
19 Persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon beta 1a dosages for multiple sclerosis. PLoS One 2013 0.89
20 Replication study of 10 genes showing evidence for association with multiple sclerosis: validation of TMEM39A, IL12B and CBLB [correction of CLBL] genes. Mult Scler 2011 0.89
21 Increasing age at disability milestones among MS patients in the MSBase Registry. J Neurol Sci 2012 0.88
22 Tag-SNP analysis of the GFI1-EVI5-RPL5-FAM69 risk locus for multiple sclerosis. Eur J Hum Genet 2010 0.87
23 Lipid-specific immunoglobulin M bands in cerebrospinal fluid are associated with a reduced risk of developing progressive multifocal leukoencephalopathy during treatment with natalizumab. Ann Neurol 2015 0.86
24 Closing the case of APOE in multiple sclerosis: no association with disease risk in over 29 000 subjects. J Med Genet 2012 0.86
25 Study of cerebral cavernous malformation in Spain and Portugal: high prevalence of a 14 bp deletion in exon 5 of MGC4607 (CCM2 gene). J Neurol 2007 0.85
26 Identification of a functional variant in the KIF5A-CYP27B1-METTL1-FAM119B locus associated with multiple sclerosis. J Med Genet 2012 0.85
27 The Kurtzke EDSS rank stability increases 4 years after the onset of multiple sclerosis: results from the MSBase Registry. J Neurol Neurosurg Psychiatry 2011 0.85
28 Adherence to interferon β-1b treatment in patients with multiple sclerosis in Spain. PLoS One 2012 0.84
29 Variable expression of cerebral cavernous malformations in carriers of a premature termination codon in exon 17 of the Krit1 gene. BMC Neurol 2003 0.84
30 Immunoglobulin M oligoclonal bands: biomarker of targetable inflammation in primary progressive multiple sclerosis. Ann Neurol 2014 0.84
31 Sex as a determinant of relapse incidence and progressive course of multiple sclerosis. Brain 2013 0.83
32 Magnetic resonance spectroscopy of normal appearing white matter in early relapsing-remitting multiple sclerosis: correlations between disability and spectroscopy. BMC Neurol 2004 0.82
33 Steatotic livers. Can we use them in OLTX? Outcome data from a prospective baseline liver biopsy study. Ann Hepatol 2012 0.81
34 Regulation by interferon beta-1a of reactive oxygen metabolites production by lymphocytes and monocytes and serum sulfhydryls in relapsing multiple sclerosis patients. Neurochem Int 2003 0.81
35 Quantitative electroencephalography reveals different physiological profiles between benign and remitting-relapsing multiple sclerosis patients. BMC Neurol 2008 0.81
36 HERV-W polymorphism in chromosome X is associated with multiple sclerosis risk and with differential expression of MSRV. Retrovirology 2014 0.81
37 Predictors and dynamics of postpartum relapses in women with multiple sclerosis. Mult Scler 2013 0.80
38 Cluster analysis of behavioural and event-related potentials during a contingent negative variation paradigm in remitting-relapsing and benign forms of multiple sclerosis. BMC Neurol 2011 0.79
39 Hexose-6-phosphate dehydrogenase: a new risk gene for multiple sclerosis. Eur J Hum Genet 2009 0.78
40 Review of the novelties presented at the 27th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (II). Rev Neurol 2012 0.78
41 Review of the novelties presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (III). Rev Neurol 2013 0.77
42 Review of the novelties presented at the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (III). Rev Neurol 2014 0.77
43 Optimization of treatment with interferon beta in multiple sclerosis. Usefulness of automatic system application criteria. BMC Neurol 2008 0.76
44 Biomarkers in multiple sclerosis: an update for 2014. Rev Neurol 2014 0.76
45 A study of promoter and intronic markers of ApoI/Fas gene and the interaction with Fas ligand in relapsing multiple sclerosis. Eur Neurol 2004 0.76
46 Retest reliability of individual p3 topography assessed by high density electroencephalography. PLoS One 2013 0.76
47 Multiple sclerosis-like illness in a HIV-1 patient. J Neurol 2004 0.75
48 Review of the novelties presented at the 27th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (I). Rev Neurol 2012 0.75
49 Aquaporins, anti-aquaporin-4 autoantibodies and neuromyelitis optica. Clin Chim Acta 2012 0.75
50 [Review of the novelties presented at the 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (I)]. Rev Neurol 2011 0.75
51 [Review of the novelties presented at the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (II)]. Rev Neurol 2014 0.75
52 Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS. Neurology 2017 0.75
53 [Biomarkers in multiple sclerosis]. Rev Neurol 2013 0.75
54 Clinical case reviews and poster sessions in multiple sclerosis spasticity: main outcomes and highlights. Eur Neurol 2014 0.75
55 Review of the novelties presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (I). Rev Neurol 2013 0.75